Disease · MONDO_0007972
Meniere disease
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Meniere disease. Diseases, record MONDO_0007972. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007972
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs23
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DIPHENHYDRAMINE | CHEMBL657 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 3 | ClinicalTrials.gov | 10 | 10 | 9 | Drugs and targets |
| EBSELEN | CHEMBL51085 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 4 | 4 | Drugs and targets |
| METHYLPREDNISOLONE | CHEMBL650 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 2 | Drugs and targets |
| FAMCICLOVIR | CHEMBL880 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GENTAMICIN | CHEMBL6067485 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| ACYCLOVIR SODIUM | CHEMBL1200380 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ISOSORBIDE | CHEMBL1200660 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| VENLAFAXINE HYDROCHLORIDE | CHEMBL1201066 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BETAHISTINE | CHEMBL24441 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 23
See all 23 drugsTargets18
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 11 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| HRH1 | Histamine H1 receptor | 2 | Histamine H1 receptor agonist; Histamine H1 receptor antagonist | Approval | https://conductscience.org/library/genes/3269 | Drugs and targets |
| SLC6A2 | Sodium-dependent noradrenaline transporter | 2 | Norepinephrine transporter inhibitor | Phase 2/3 | https://conductscience.org/library/genes/6530 | Drugs and targets |
| HRH3 | Histamine H3 receptor | 1 | Histamine H3 receptor antagonist | Phase 2 | https://conductscience.org/library/genes/11255 | Drugs and targets |
| IL1R1 | Interleukin-1 receptor type 1 | 1 | Interleukin-1 receptor antagonist | Phase 2 | https://conductscience.org/library/genes/3554 | Drugs and targets |
| PTGFR | Prostaglandin F2-alpha receptor | 1 | Prostanoid FP receptor agonist | Phase 2 | https://conductscience.org/library/genes/5737 | Drugs and targets |
| SCN10A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6336 | Drugs and targets |
| SCN11A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/11280 | Drugs and targets |
| SCN1A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6323 | Drugs and targets |
| SCN2A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6326 | Drugs and targets |
1 to 10 of 18
See all 18 targetsTrials26
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02706730 | A 6-Month Extension Study of OTO-104 in Meniere's Disease | Phase 3 | 189 | 2022-12-14 | Meniere's Disease | DEXAMETHASONE | Its record names the disease | ClinicalTrials.gov |
| NCT02717442 | Study of OTO-104 in Subjects With Unilateral Meniere's Disease | Phase 3 | 176 | 2023-01-13 | Meniere's Disease | DEXAMETHASONE | Its record names the disease | ClinicalTrials.gov |
| NCT02612337 | Study of OTO-104 in Subjects With Unilateral Meniere's Disease | Phase 3 | 166 | 2023-01-12 | Meniere's Disease | DEXAMETHASONE | Its record names the disease | ClinicalTrials.gov |
| NCT03325790 | SPI-1005 for the Treatment of Patients With Meniere's Disease | Phase 2 | 149 | 2023-08-14 | Meniere's Disease | EBSELEN | Its record names the disease | ClinicalTrials.gov |
| NCT03664674 | Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease | Phase 3 | 148 | 2022-12-07 | Meniere Disease | DEXAMETHASONE | Its record names the disease | ClinicalTrials.gov |
| NCT02768662 | A 6-Month Extension Study of OTO-104 in Meniere's Disease | Phase 3 | 142 | 2023-01-20 | Meniere's Disease | DEXAMETHASONE | Its record names the disease | ClinicalTrials.gov |
| NCT00802529 | Transtympanic Gentamicin vs. Steroids in Refractory Meniere's Disease | Phase 2/3 | 60 | 2016-10-24 | Meniere's Disease | GENTAMICIN, METHYLPREDNISOLONE | Its record names the disease | ClinicalTrials.gov |
| NCT04218123 | Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes | Phase 2/3 | 40 | 2024-06-24 | Meniere Disease | VENLAFAXINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02158585 | Study of Lamotrigine to Treat Ménière's Disease | Phase 2 | 15 | 2022-06-22 | Meniere's Disease, Ménière's Vertigo, Vertigo, Intermittent, Vertigo, Aural | LAMOTRIGINE | Its record names the disease | ClinicalTrials.gov |
| NCT01526408 | Famvir for Treatment of Hearing in Unilateral Meniere's Disease | Phase 3 | 11 | 2021-04-19 | Meniere's Disease | FAMCICLOVIR | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 26
See all 26 trialsComparisons in its trials26
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| OTO-104 (Safety Analysis Set) vs Placebo (Safety Analysis Set): deaths from any cause | 0 of 86 | 0 of 88 | 174 | NCT02717442 | Trial comparisons |
| OTO-104 (Safety Analysis Set) vs Placebo (Safety Analysis Set): serious adverse events | 2 of 86 | 0 of 88 | 174 | NCT02717442 | Trial comparisons |
| OTO-104 (Safety Analysis Set) vs Placebo (Safety Analysis Set): Otoscopic Examination - Tympanic Membrane Perforation at Week 12 (Month 3) | 4 of 82 | 0 of 83 | 165 | NCT02612337 | Trial comparisons |
| OTO-104 (Safety Analysis Set) vs Placebo (Safety Analysis Set): deaths from any cause | 0 of 82 | 0 of 83 | 165 | NCT02612337 | Trial comparisons |
| OTO-104 (Safety Analysis Set) vs Placebo (Safety Analysis Set): serious adverse events | 2 of 82 | 2 of 83 | 165 | NCT02612337 | Trial comparisons |
| OTO-104 (Safety Analysis Set) vs Placebo (Safety Analysis Set): Audiometry - Shift in Air-Bone Gap at 2000 Hz From Baseline to Week 12 (Month 3) | 4 of 74 | 1 of 78 | 152 | NCT02612337 | Trial comparisons |
| OTO-104 vs Placebo: Otoscopic Examination - Presence of Perforation in the Treated Ear at Week 12 (Month 3) Final Visit | 0 of 73 | 0 of 75 | 148 | NCT03664674 | Trial comparisons |
| OTO-104 vs Placebo: deaths from any cause | 0 of 73 | 0 of 75 | 148 | NCT03664674 | Trial comparisons |
| OTO-104 vs Placebo: serious adverse events | 2 of 73 | 2 of 75 | 148 | NCT03664674 | Trial comparisons |
| OTO-104 (Safety Analysis Set) vs Placebo (Safety Analysis Set): Audiometry - Shift in Air-Bone Gap at 1000 Hz From Baseline to Week 12 (Month 3) | 3 of 70 | 3 of 68 | 138 | NCT02612337 | Trial comparisons |
1 to 10 of 26
See all 26 comparisons in its trialsPapers from its trials10
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007972
GET https://conductscience.org/api/diseases/v1/MONDO_0007972/drugs?page=2